FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2042303659> ?p ?o ?g. }

• W2042303659 endingPage "452" @default.
• W2042303659 startingPage "443" @default.
• W2042303659 abstract "The major cause for failure of autologous stem cell transplantation for hematologic malignancies is the risk of recurrent disease. As a result, new treatment regimens that include novel agents or combinations of agents and approaches are needed. The current report describes a large Phase I/II, single-center trial that includes 60 patients with a variety of hematologic malignancies. These patients received a fixed dose of carboplatin (1 g/m(2)/d x 72 hours by CI) etoposide (600 mg/m(2)/d x 3 days) and cyclophosphamide (2 g/m(2)/d x 3 days), plus escalating doses of total body irradiation (TBI) (at 1000, 1200, and 1295 cGy) over 3 days. Eleven patients received infusion of autologous marrow, 32 received peripheral blood stem cells, and 17 patients received both. The maximum tolerated dose of this regimen was a radiation dose of 1200 cGy given in 200-cGy fractions BID x 3 days. The dose-limiting toxicity was mucositis, with 97% of patients requiring narcotic analgesia for mouth pain. Overall treatment-related mortality was 6.7%, with 2 of the 4 deaths occurring in a group of 9 patients aged 60 and older. Responses were seen in all patient groups, but the most encouraging outcomes were seen in 12 patients with high-risk or advanced acute myelocytic lymphoma (AML), 7 of whom remain alive and free of disease beyond 5 years. This regimen is intensive and causes considerable mucositis but is otherwise well tolerated and has demonstrated activity in a number of hematologic malignancies, especially AML." @default.
• W2042303659 created "2016-06-24" @default.
• W2042303659 creator A5000056684 @default.
• W2042303659 creator A5001098812 @default.
• W2042303659 creator A5007727125 @default.
• W2042303659 creator A5016236611 @default.
• W2042303659 creator A5026510629 @default.
• W2042303659 creator A5048057394 @default.
• W2042303659 creator A5051396047 @default.
• W2042303659 creator A5053291056 @default.
• W2042303659 creator A5070815162 @default.
• W2042303659 creator A5079494408 @default.
• W2042303659 creator A5083713013 @default.
• W2042303659 date "2003-07-01" @default.
• W2042303659 modified "2023-10-11" @default.
• W2042303659 title "An expanded phase I/II trial of cyclophosphamide, etoposide, and carboplatin plus total body irradiation with autologous marrow or stem cell support for patients with hematologic malignancies" @default.
• W2042303659 cites W1497143314 @default.
• W2042303659 cites W16103346 @default.
• W2042303659 cites W1789478788 @default.
• W2042303659 cites W1807744984 @default.
• W2042303659 cites W1822252547 @default.
• W2042303659 cites W1842391090 @default.
• W2042303659 cites W1846648891 @default.
• W2042303659 cites W1877303819 @default.
• W2042303659 cites W1888347784 @default.
• W2042303659 cites W1922664920 @default.
• W2042303659 cites W1937538988 @default.
• W2042303659 cites W1953803500 @default.
• W2042303659 cites W1990892742 @default.
• W2042303659 cites W1997353354 @default.
• W2042303659 cites W2018775713 @default.
• W2042303659 cites W2038465924 @default.
• W2042303659 cites W2058900796 @default.
• W2042303659 cites W2111783699 @default.
• W2042303659 cites W2135001035 @default.
• W2042303659 cites W2142334769 @default.
• W2042303659 cites W2166820806 @default.
• W2042303659 cites W2167300548 @default.
• W2042303659 cites W2176980523 @default.
• W2042303659 cites W2197955157 @default.
• W2042303659 cites W2207262939 @default.
• W2042303659 cites W2253178268 @default.
• W2042303659 cites W2253580546 @default.
• W2042303659 cites W2262560243 @default.
• W2042303659 cites W2339293928 @default.
• W2042303659 cites W3145716452 @default.
• W2042303659 cites W321206321 @default.
• W2042303659 cites W329934425 @default.
• W2042303659 cites W4246790039 @default.
• W2042303659 cites W4377834542 @default.
• W2042303659 doi "https://doi.org/10.1016/s1083-8791(03)00204-0" @default.
• W2042303659 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12869958" @default.
• W2042303659 hasPublicationYear "2003" @default.
• W2042303659 type Work @default.
• W2042303659 sameAs 2042303659 @default.
• W2042303659 citedByCount "11" @default.
• W2042303659 countsByYear W20423036592012 @default.
• W2042303659 countsByYear W20423036592015 @default.
• W2042303659 countsByYear W20423036592017 @default.
• W2042303659 crossrefType "journal-article" @default.
• W2042303659 hasAuthorship W2042303659A5000056684 @default.
• W2042303659 hasAuthorship W2042303659A5001098812 @default.
• W2042303659 hasAuthorship W2042303659A5007727125 @default.
• W2042303659 hasAuthorship W2042303659A5016236611 @default.
• W2042303659 hasAuthorship W2042303659A5026510629 @default.
• W2042303659 hasAuthorship W2042303659A5048057394 @default.
• W2042303659 hasAuthorship W2042303659A5051396047 @default.
• W2042303659 hasAuthorship W2042303659A5053291056 @default.
• W2042303659 hasAuthorship W2042303659A5070815162 @default.
• W2042303659 hasAuthorship W2042303659A5079494408 @default.
• W2042303659 hasAuthorship W2042303659A5083713013 @default.
• W2042303659 hasBestOaLocation W20423036591 @default.
• W2042303659 hasConcept C126322002 @default.
• W2042303659 hasConcept C141071460 @default.
• W2042303659 hasConcept C2776694085 @default.
• W2042303659 hasConcept C2776755627 @default.
• W2042303659 hasConcept C2778119113 @default.
• W2042303659 hasConcept C2778239845 @default.
• W2042303659 hasConcept C2778496288 @default.
• W2042303659 hasConcept C2778880498 @default.
• W2042303659 hasConcept C2781413609 @default.
• W2042303659 hasConcept C2781451048 @default.
• W2042303659 hasConcept C71924100 @default.
• W2042303659 hasConcept C90924648 @default.
• W2042303659 hasConceptScore W2042303659C126322002 @default.
• W2042303659 hasConceptScore W2042303659C141071460 @default.
• W2042303659 hasConceptScore W2042303659C2776694085 @default.
• W2042303659 hasConceptScore W2042303659C2776755627 @default.
• W2042303659 hasConceptScore W2042303659C2778119113 @default.
• W2042303659 hasConceptScore W2042303659C2778239845 @default.
• W2042303659 hasConceptScore W2042303659C2778496288 @default.
• W2042303659 hasConceptScore W2042303659C2778880498 @default.
• W2042303659 hasConceptScore W2042303659C2781413609 @default.
• W2042303659 hasConceptScore W2042303659C2781451048 @default.
• W2042303659 hasConceptScore W2042303659C71924100 @default.
• W2042303659 hasConceptScore W2042303659C90924648 @default.
• W2042303659 hasIssue "7" @default.
• W2042303659 hasLocation W20423036591 @default.

• next